Patents by Inventor Jeffrey T. L. Smith

Jeffrey T. L. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10800841
    Abstract: Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 13, 2020
    Assignee: VITAERIS, INC.
    Inventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, John Latham, Brian R. Kovacevich, Jeffrey T. L. Smith
  • Publication number: 20200317772
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: October 8, 2020
    Inventors: Andrew Lawrence FELDHAUS, Leon GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katie Olson ANDERSON, Ethan Wayne OJALA, Pei FAN, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Jeffrey T.L. SMITH, John LATHAM
  • Patent number: 10787511
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: September 29, 2020
    Assignee: VITAERIS INC.
    Inventor: Jeffrey T. L. Smith
  • Patent number: 10787507
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 29, 2020
    Assignee: VITAERIS INC.
    Inventor: Jeffrey T. L. Smith
  • Publication number: 20200299368
    Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Application
    Filed: February 18, 2020
    Publication date: September 24, 2020
    Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler
  • Patent number: 10765746
    Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: September 8, 2020
    Assignees: ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
  • Patent number: 10759853
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 1, 2020
    Assignee: Alderbio Holdings LLC
    Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
  • Publication number: 20200216524
    Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler
  • Publication number: 20200216525
    Abstract: Methods for treatment or prevention of medication overuse headache are provided. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Application
    Filed: January 8, 2020
    Publication date: July 9, 2020
    Inventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler
  • Publication number: 20200181230
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 11, 2020
    Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
  • Publication number: 20200181229
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 11, 2020
    Inventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T.L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Publication number: 20200172612
    Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 4, 2020
    Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
  • Publication number: 20200165316
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 28, 2020
    Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRIX, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
  • Publication number: 20200140539
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.
    Type: Application
    Filed: July 22, 2019
    Publication date: May 7, 2020
    Inventor: Jeffrey T.L. Smith
  • Patent number: 10640560
    Abstract: The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: May 5, 2020
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Jeffrey T. L. Smith, John A. Latham, Mark Litton, Randall Schatzman
  • Publication number: 20200108140
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or anti-body fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of lift of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (oral risk of developing) an elevated serum C-reactive protein level reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
    Type: Application
    Filed: August 26, 2019
    Publication date: April 9, 2020
    Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, John A. Latham, Brian R. Kovacevich, Jeffrey T.L. Smith, Mark Litton, Randall Schatzman
  • Publication number: 20200093921
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.
    Type: Application
    Filed: October 3, 2019
    Publication date: March 26, 2020
    Inventor: Jeffrey T.L. Smith
  • Publication number: 20200087391
    Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
    Type: Application
    Filed: May 24, 2019
    Publication date: March 19, 2020
    Inventors: Leon F. GARCIA-MARTINEZ, Anne Elisabeth CARVALHO JENSEN, Katie ANDERSON, Benjamin H. DUTZAR, Ethan W. OJALA, Brian R. KOVACEVICH, John A. LATHAM, Jeffrey T.L. SMITH
  • Publication number: 20200079847
    Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
    Type: Application
    Filed: January 8, 2019
    Publication date: March 12, 2020
    Inventors: Maria-Cristina LOOMIS, Leon F. GARCIA-MARTINEZ, Benjamin H. DUTZAR, Daniel S. ALLISON, Katherine Lee HENDRICKS, Ethan W. OJALA, Pei FAN, Jeffrey T.L. SMITH, John A. LATHAM, Charlie KARASEK, Jenny MULLIGAN, Michelle SCALLEY-KIM, Erica STEWART, Vanessa Lisbeth RUBIN, Jens J. BILLGREN
  • Publication number: 20200062838
    Abstract: This invention pertains to monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 27, 2020
    Inventors: Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan W. Ojala, Jeffrey T.L. Smith, John A. Latham